Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 4/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.40 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | PPARA | Q07869 | 6/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604517 | 0.98 | RELA (0.46) | RELAPLA2G2AGPR84PPARGPPARD | |
| SCHEMBL10559242 | 0.98 | RELA (0.46) | RELAPLA2G2AGPR84PPARGPPARD | |
| SCHEMBL14173629 | 0.98 | RELA (0.46) | RELAPLA2G2AGPR84PPARGPPARD | |
| SCHEMBL11521699 | 0.98 | RELA (0.46) | RELAPLA2G2AGPR84PPARGPPARD | |
| SCHEMBL10897013 | 0.94 | MMP8 (0.44) | RELAMMP8MMP12MMP13PLA2G2A | |
| SCHEMBL6884784 | 0.88 | FAAH (0.45) | RELAMMP8MMP12MMP13PLA2G2A | |
| SCHEMBL10359258 | 0.85 | MMP12 (0.46) | MMP8MMP12MMP13PLA2G2ATSHR | |
| SCHEMBL10354513 | 0.83 | CES1 (0.40) | RELA | |
| SCHEMBL10895115 | 0.81 | RELA (0.49) | RELAPLA2G2AAKR1B1GPR84PPARG | |
| SCHEMBL7836224 | 0.81 | RELA (0.35) | RELAMMP8MMP12MMP13AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | claimed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | claimed |
| EP-2121600-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | claimed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | BILLLEDEAU ROLAND JOSEPH (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030199520-A1 | Sulfonamide hydroxamates | BILLLEDEAU ROLAND JOSEPH (US) | 2003-10-23 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
| EP-1214301-A1 | HYPOGLYCEMIC N,N-ARYLSULFONYLGLYCINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1149072-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001016119-A1 | HYPOGLYCEMIC N,N-ARYLSULFONYLGLYCINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000037436-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| US-4632931-A | ANTICOAGULANTS, BRONCHODILATOR AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | CTSE, PREP, HPN | RELA 3510/4885MMP8 35/4885MMP12 101/4885 |
| US-20030199520-A1 | Sulfonamide hydroxamates | MMP3, TIMP3, MMP13 | RELA 3677/4885MMP8 38/4885MMP12 62/4885 |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | RELA 3404/4885MMP8 4589/4885MMP12 3636/4885 |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | RELA 3256/4885MMP8 3584/4885MMP12 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.